
RealRate

PHARMACEUTICAL 2017

MERRIMACK PHARMACEUTICALS **INC** Rank 231 of 313



RealRate

PHARMACEUTICAL 2017

MERRIMACK PHARMACEUTICALS INC Rank 231 of 313

The relative strengths and weaknesses of MERRIMACK PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MERRIMACK PHARMACEUTICALS INC compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 178% points. The greatest weakness of MERRIMACK PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 258% points.

The company's Economic Capital Ratio, given in the ranking table, is -432%, being 15% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	57,435
Cost of Goods Sold	6,912
Intangible Assets	7,582
Liabilities, Current	88,222
Liabilities, Non-Current	216,861
Other Assets	701
Other Compr. Net Income	1,778
Other Expenses	49,501
Other Liabilities	29,059
Other Net Income	268
Property and Equipment	15,765
Research and Development	160,917
Revenues	144,273
Selling, General and Administrative Expense	80,729

Output Variable	Value in 1000 USD
Assets	81,483
Liabilities	334,142
Expenses	298,059
Stockholders Equity	-252,659
Net Income	-153,518
Comprehensive Net Income	-152,629
Economic Capital Ratio	-432%